Mymetics Corp (MYMX)

[Work Harder]

Associated Data Supplementary Materials 2 of 2

Word doc

Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges

Immune-Tech

HIV-1 gp41 MN

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902080/

HIV1 gp41 MN Recombinant Protein

DISCONTINUED
You will be redirected to our replacement product in 1 seconds.

https://www.mybiosource.com/recombinant-protein/hiv1-gp41-mn/536953

w/

HIV-1 gp41 Long Recombinant Protein

Popular Item

https://www.mybiosource.com/recombinant-protein/hiv-1-gp41-long/142607

Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated

HIV-1 gp41 MN

1Duke Human Vaccine Institute, 2Department of Medicine, 3Department of Pediatrics, 4Department of Surgery, 5Department of Immunology, and 6Center for Computational Immunology, Duke University School of Medicine, Durham, NC 27710
7The Aaron Diamond AIDS Research Center, New York, NY 10016
8University of Alabama-Birmingham, Birmingham, AL 35294
9University of North Carolina at Chapel Hill, Chapel Hill, NC 27599
10Department of Pathology, Stanford School of Medicine, Stanford, CA 94305
11454 Life Sciences, Branford, CT 06405
12GlaxoSmithKline Biologicals, 1330 Rixensart, Belgium
corresponding authorCorresponding author.
CORRESPONDENCE Hua-Xin Liao: ude.ekud@oailh OR Barton F. Haynes: ude.ekud.cm@200enyah
X. Chen, S. Munshaw, G. Tomaras, M.A. Moody, and T.B. Kepler contributed equally to this paper.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201211/

Recombinant HIV-1 MN gp41 Envelope Protein (E.coli)

New

rgp41 HIV-1 MN(E.coli)

https://immunodx.com/products/rgp41-hiv-1-mne-coli

Structure of HIV-1 gp41 with its membrane anchors targeted by neutralizing antibodies

Acknowledgements

WW acknowledges support from the Institut Universitaire de France (IUF), from the European Union's Horizon 2020 research and innovation program under grant agreement No. 681137, H2020 EAVI and the platforms of the Grenoble Instruct-ERIC center (IBS and ISBG; UMS 3518 CNRS-CEA-UGA-EMBL) within the Grenoble Partnership for Structural Biology (PSB). Platform access was supported by FRISBI (ANR-10-INBS-05–02) and GRAL, a project of the University Grenoble Alpes graduate school (Ecoles Universitaires de Recherche) CBH-EUR-GS (ANR-17-EURE-0003). IBS is part of the CEA DRF Interdisciplinary Research Institute of Grenoble (IRIG). JLN acknowledges funding from Spanish MCIU (RTI2018-095624-B-C21; MCIU/AEI/FEDER, UE) and Basque Government (IT1196-19). We thank Miriam Hock and Serafima Guseva for previous contributions to the project, Davide Corti for providing bnAb LN01, the ESRF-EMBL Joint Structural Biology Group for access and support at the ESRF beam lines, J Marquez (EMBL) from the HTX crystallization facility and C Mas and J-B Reiser for assistance on ISBG platforms.

https://elifesciences.org/articles/65005

Davide Corti. Senior Vice President, Antibody Research presso Vir Biotechnology

w/ a Gsk & B&M Gates equity investment

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168092687

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167270024

Rally time yet again so lets hear it for the monkeys lol